Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dostarlimab by GSK for Gastric Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Pancreatic Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase III for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Dostarlimab by GSK for Oropharyngeal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III...
Dostarlimab by GSK for Laryngeal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase III...
Dostarlimab by GSK for Hypopharyngeal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase III...
Dostarlimab by GSK for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Dostarlimab by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Dostarlimab by GSK for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Dostarlimab by GSK for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...
Dostarlimab by GSK for Duodenal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Duodenal Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Soft Tissue Sarcoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...
Dostarlimab by GSK for Vulvar Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Vaginal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Hepatocellular Carcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Dostarlimab by GSK for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC)....